Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation breached their fiduciary duties to shareholders. The investigation focuses on potential corporate misconduct and the impact on shareholder value. Shareholders may be able to seek corporate governance reforms, the return of funds to the company, or a court-approved financial incentive award.

The firm represents investors globally who have been affected by securities fraud and corporate misconduct. Halper Sadeh LLC has previously implemented corporate reforms and recovered millions of dollars for defrauded investors. Shareholder involvement is emphasized as a means to improve company policies, practices, and oversight mechanisms.

Potential Outcomes for Shareholders

If the investigation reveals breaches, shareholders may pursue several forms of relief:

• Corporate governance reforms
• Return of funds to the company
• Court-approved financial incentive awards
• Other relief and benefits

Contact Information

Shareholders currently holding Edwards stock, particularly long-term shareholders, are advised to contact the firm promptly. Daniel Sadeh and Zachary Halper are available at (212) 763-0060 or via email at sadeh@halpersadeh.com or zhalper@halpersadeh.com . The firm operates on a contingent fee basis, meaning shareholders are not responsible for out-of-pocket legal fees or expenses.

Edwards Lifesciences presented new data at New York Valves 2026, reinforcing its leadership in advancing high-quality scientific evidence for structural heart therapies. The data, spanning aortic, mitral, and tricuspid therapies, provide insights into the complexity of structural heart disease and the need for innovative treatment options. The findings were presented at the annual conference organized by the Cardiovascular Research Foundation.

PROGRESS Trial Baseline Characteristics

The baseline characteristics of the PROGRESS trial offer new insights into the heterogeneous nature of moderate aortic stenosis (AS) patients. The trial evaluates whether patients with moderate AS and at least one risk factor may benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines. Key characteristics include:

SAPIEN Platform Durability and EARLY TAVR Findings

Late-breaking clinical science presentations strengthen the evidence base for the SAPIEN 3 platform. This includes seven-year benchmark durability data from the PARTNER 3 trial, simultaneously published in JAMA Cardiology. New findings from the EARLY TAVR trial reinforce the shift toward proactive disease management, providing long-term reassurance for physicians and patients.

Mitral and Tricuspid Portfolio Outcomes

New data highlighted clinical trial and real-world outcomes across Edwards’ mitral and tricuspid portfolio. Data from more than 4,500 patients treated with the PASCAL system in the STS/ACC Transcatheter Valve Therapy Registry demonstrate sustained safety and effectiveness for mitral regurgitation (MR). One-year data from the ENCIRCLE trial Mitral Annular Calcification (MAC) Registry support the safety, effectiveness, and quality of life improvements with SAPIEN M3, the first transcatheter transseptal mitral valve replacement system.

Bernard Zovighian, Edwards’ CEO, emphasized the company's commitment to addressing unmet needs and advancing care through partnerships with the physician community. The expanding evidence base aims to strengthen confidence in long-term outcomes and increase access for patients worldwide.